Alnylam Rallies 62% in a Year: Can the Stock Maintain This Momentum?
Portfolio Pulse from
Alnylam Pharmaceuticals (ALNY) has seen a 62% increase in its stock price over the past year, primarily due to rising sales of its products Amvuttra and Givlaari. The company is also benefiting from successful collaboration deals with Roche (RHHBY), Novartis (NVS), and Regeneron (REGN).
March 14, 2025 | 1:00 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Alnylam Pharmaceuticals has experienced a 62% stock price increase over the past year, driven by strong sales of Amvuttra and Givlaari, and successful collaborations with major pharmaceutical companies.
The significant increase in ALNY's stock price is attributed to the strong sales performance of its key products and the positive progress in its collaborations with major companies like Roche, Novartis, and Regeneron. This suggests a positive outlook for the company's future performance.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100